Kirby Institute

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Established: 1986-01-01

Employees: 101

Market Cap: -

Website: https://kirby.unsw.edu.au

Clinical Trials

Surveillance and Treatment of Prisoners With Hepatitis C

Phase 4

Completed

Conditions: Hepatitis C

Interventions: Drug: Sofosbuvir/velpatasvir

First Posted Date: 2014-02-17

Last Posted Date: 2019-12-09

Lead Sponsor: Kirby Institute

Target Recruit Count: 3692

Registration Number: NCT02064049

Locations: 🇦🇺
Goulburn Correctional Centre, Goulburn, New South Wales, Australia
🇦🇺
Dillwynia Correctional Centre, Windsor, New South Wales, Australia
🇦🇺
Outer Metropolitan Multipurpose Correctional Centre, Windsor, New South Wales, Australia

and more 1 locations

Study of the Prevention of Anal Cancer

Not Applicable

Completed

Conditions: Human Papillomavirus
Cancer

Interventions: Procedure: Participants asked questions about recent experiences of anal intercourse in the last six months.
Procedure: High Resolution Anoscopy

First Posted Date: 2013-12-10

Last Posted Date: 2019-12-02

Lead Sponsor: Kirby Institute

Target Recruit Count: 617

Registration Number: NCT02007421

Locations: 🇦🇺
RPA Sexual Health, Royal Prince Alfred Hospital, Camperdown, Sydney, New South Wales, Australia
🇦🇺
Applied Medical Research (AMR CRP), St. Vincent's Hospital, Sydney, New South Wales, Australia

Australian Trial in Acute Hepatitis C Recall Study

Completed

Conditions: Acute Hepatitis C

First Posted Date: 2013-12-03

Last Posted Date: 2014-10-01

Lead Sponsor: Kirby Institute

Target Recruit Count: 50

Registration Number: NCT02000063

Locations: 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia

DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)

Phase 4

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: TPV/PEG-IFN/RBV

First Posted Date: 2012-12-06

Last Posted Date: 2017-03-29

Lead Sponsor: Kirby Institute

Target Recruit Count: 14

Registration Number: NCT01743521

Locations: 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

MARCH Central Nervous System Substudy

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors
Drug: Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors
Drug: Arm 2 Maraviroc and Protease Inhibitors

First Posted Date: 2012-07-11

Last Posted Date: 2016-01-20

Lead Sponsor: Kirby Institute

Target Recruit Count: 28

Registration Number: NCT01637233

Locations: 🇦🇷
Hospital Ramos Mejía, Buenos Aires, Argentina
🇦🇷
Fundación IDEAA, Buenos Aires, Argentina
🇦🇷
CAICI, Rosario, Argentina

and more 3 locations

MARCH Renal Substudy

Phase 4

Completed

Conditions: HIV
Proteinuria

Interventions: Drug: arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors
Drug: Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc
Drug: Arm 2 boosted protease inhibitors and maraviroc

First Posted Date: 2012-07-11

Last Posted Date: 2016-01-20

Lead Sponsor: Kirby Institute

Target Recruit Count: 76

Registration Number: NCT01637259

Locations: 🇬🇧
Brighton & Sussex University NHS Trust, Brighton, Sussex, United Kingdom
🇦🇺
Brisbane Sexual Health and HIV Service, Brisbane, Queensland, Australia
🇩🇪
Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie, MX-Ambulanz, Dusseldorf, Germany

and more 12 locations

MARCH Vascular Endothelium Substudy

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: NRTI + PI
Drug: maraviroc + NRTI
Drug: maraviroc + PI

First Posted Date: 2012-04-26

Last Posted Date: 2016-01-20

Lead Sponsor: Kirby Institute

Target Recruit Count: 34

Registration Number: NCT01585753

Locations: 🇦🇷
Fundacion IDEAA, Buenos Aires, Argentina
🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
🇩🇪
Johann Wolfgang Goethe-University Hospital, Medical HIVCENTER, Frankfurt, Frankfurt am Main, Germany

and more 3 locations

The Neurocognitive Sub-study of Encore1

Phase 3

Completed

Conditions: HIV

Interventions: Drug: Efavirenz

First Posted Date: 2012-01-24

Last Posted Date: 2013-09-19

Lead Sponsor: Kirby Institute

Target Recruit Count: 71

Registration Number: NCT01516060

Locations: 🇹🇭
HIVNAT Research Collaboration, Bangkok, Thailand

Bone and Body Comp: A Sub Study of the SECOND-LINE Study

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Lopinavir / ritonavir
Drug: 2-3N(t)RTI
Drug: raltegravir

First Posted Date: 2012-01-20

Last Posted Date: 2019-09-04

Lead Sponsor: Kirby Institute

Target Recruit Count: 210

Registration Number: NCT01513122

Locations: 🇿🇦
Desmond Tutu HIV Foundation, Cape Town, South Africa
🇦🇷
CEADI, Buenos Aires, Argentina
🇹🇭
HIV-NAT Program on AIDS - Thai Red Cross, Bangkok, Thailand

and more 4 locations

The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1

Phase 3

Completed

Conditions: HIV Infection

Interventions: Drug: Efavirenz

First Posted Date: 2011-10-13

Last Posted Date: 2013-05-13

Lead Sponsor: Kirby Institute

Target Recruit Count: 32

Registration Number: NCT01451333

Locations: 🇹🇭
Khon Kaen University, Khon Kaen, Thailand
🇩🇪
Medical Group Practice, Berlin, Germany
🇹🇭
HIVNAT Research Collaboration, Patumwan, Bangkok, Thailand

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy